| Type 1 interferons as a potential treatment against COVID-19 E Sallard, FX Lescure, Y Yazdanpanah, F Mentre, N Peiffer-Smadja, ... Antiviral Research, 104791, 2020 | 624 | 2020 |
| Tracing the origins of SARS-COV-2 in coronavirus phylogenies: a review E Sallard, J Halloy, D Casane, E Decroly, J van Helden Environmental Chemistry Letters 19 (2), 769-785, 2021 | 135* | 2021 |
| Electrophysiology of ionotropic GABA receptors E Sallard, D Letourneur, P Legendre Cellular and Molecular Life Sciences 78 (13), 5341-5370, 2021 | 95 | 2021 |
| Attenuation of heparan sulfate proteoglycan binding enhances in vivo transduction of human primary hepatocytes with AAV2 M Cabanes-Creus, A Westhaus, RG Navarro, G Baltazar, E Zhu, ... Molecular Therapy-Methods & Clinical Development 17, 1139-1154, 2020 | 42 | 2020 |
| The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine E Sallard, W Zhang, M Aydin, K Schröer, A Ehrhardt Viruses 15 (1), 204, 2023 | 26 | 2023 |
| AAV-p40 bioengineering platform for variant selection based on transgene expression A Westhaus, M Cabanes-Creus, T Jonker, E Sallard, RG Navarro, E Zhu, ... Human Gene Therapy 33 (11-12), 664-682, 2022 | 24 | 2022 |
| Simplified point-of-care full SARS-CoV-2 genome sequencing using nanopore technology A Pembaur, E Sallard, PP Weil, J Ortelt, P Ahmad-Nejad, J Postberg Microorganisms 9 (12), 2598, 2021 | 22 | 2021 |
| Current and Prospective Applications of CRISPR-Cas12a in Pluricellular Organisms S Khan, E Sallard Molecular Biotechnology, 1-10, 2022 | 16 | 2022 |
| Novel group C oncolytic adenoviruses carrying a microRNA inhibitor demonstrate enhanced oncolytic activity in vitro and in vivo J Doerner, E Sallard, W Zhang, M Solanki, J Liu, E Ehrke-Schulz, ... Molecular Cancer Therapeutics, 2022 | 15 | 2022 |
| Viral Infection and Respiratory Exacerbation in Children: Results from a Local German Pediatric Exacerbation Cohort E Sallard, F Schult, C Baehren, E Buedding, O Mboma, P Ahmad-Nejad, ... Viruses 14 (3), 491, 2022 | 10 | 2022 |
| Anticovid, a comprehensive open-access real-time platform of registered clinical studies for COVID-19 N Peiffer-Smadja, FX Lescure, E Sallard, P Ravaud, B Vegreville, ... Journal of Antimicrobial Chemotherapy 75 (9), 2708-2710, 2020 | 8 | 2020 |
| Clinical trial protocols of repurposed prophylaxis for COVID-19: a review E Sallard, D Belhadi, FX Lescure, Y Yazdanpanah, N Peiffer-Smadja Médecine et Maladies Infectieuses, 2020 | 7* | 2020 |
| Adenovirus type 34 and HVR1-deleted adenovirus type 5 do not bind to PF4: clearing the path towards vectors without thrombosis risk E Sallard, D Pembaur, K Schröer, S Schellhorn, G Koukou, N Schmidt, ... bioRxiv, 2022.11. 07.515483, 2022 | 6 | 2022 |
| Combining CRISPR-Cas-mediated terminal resolution with a novel genetic workflow to achieve high-diversity adenoviral libraries J Fischer, A Fedotova, L Jaki, E Sallard, A Erhardt, J Fuchs, Z Ruzsics Molecular Therapy Methods & Clinical Development 32 (2), 2024 | 3 | 2024 |
| In Vitro Analysis of the Effect of SARS-CoV-2 Non-VOC and four Variants of Concern on MHC-Class-I Expression on Calu-3 and Caco-2 Cells NA Bahlmann, L Mautner, M Hoyos, E Sallard, C Berger, A Dangel, ... Genes 14 (7), 1348, 2023 | 3 | 2023 |
| Microarray-Based Analyses of Rhinovirus Species-Specific Antibody Responses in Exacerbated Pediatric Asthma in a German Pediatric Cohort E Sallard, K Niespodziana, M Bajic, T Schlederer, P Errhalt, AK Behrendt, ... Viruses 14 (9), 1857, 2022 | 3 | 2022 |
| Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5 E Sallard, L Schulte, A van den Boom, A Klimovitskii, J Knierer, ... The Journal of Gene Medicine, e3576, 2023 | 2 | 2023 |
| ADEVO: Proof-of-concept of adenovirus-directed EVOlution by random peptide display on the fiber knob E Sallard, J Fischer, K Schroeer, LM Dawson, N Beaude, A Affes, ... Molecular Therapy Oncology 32 (4), 2024 | | 2024 |
| Cutting-edge research frontiers in oral cavity vaccines for respiratory diseases: a roadmap for scientific advancement E Sallard, M Aydin Frontiers in Cellular and Infection Microbiology 14, 1388222, 2024 | | 2024 |
| Targeting Oncolytic Adenoviruses to Cancer Cells Using a Designed Ankyrin Repeat Protein Lipocalin-2 Fusion Protein S Schellhorn, D Brücher, NA Wolff, K Schröer, E Sallard, K Mese, ... Human Gene Therapy 34 (5-6), 203-216, 2023 | | 2023 |
Nathan Peiffer-SmadjaAssociate Professor, Université Paris Cité, Assistance Publique Hôpitaux de Paris在 aphp.fr 的电子邮件经过验证
